GUJARAT THEMIS BIOSYN LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated |
|---|
| Revenue |
| EBITDA (ex other income) |
| margin % |
| Owners' profit |
| EPS, as reported (₹) |
| ROE % · ROCE % |
| Debt / equity (x) |
| Cash from operations |
| Capex |
| ₹ crore | Q1 FY27 |
|---|---|
| Revenue | 44 |
| Profit before tax | 15 |
| Net profit | 11 |
| EPS (₹) | 1.02 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Board approves NCD issuance of up to INR 585 Crores via private placement | board shareholder meetings | low | — | — |
| 8 Sept 2026 · Addendum to 45th AGM notice with fund raising and dividend resolutions | board shareholder meetings | low | — | — |
| 7 Sept 2026 · Board meeting on 10 Sep 2026 to consider NCD private placement | fund raising | medium | — | — |
| 7 Sept 2026 · Gujarat Themis Biosyn - 45th AGM Notice Published in Newspapers | compliance | minimal | — | — |
| 4 Sept 2026 · Gujarat Themis Biosyn 45th AGM notice on September 30, 2026 | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Promoter stake dilutes to 59.33% after QIP share allotment | ownership changes | medium | — | — |
| 1 Sept 2026 · Board approves preferential issue worth up to Rs 335 crore to promoter group and four investors | fund raising | medium | — | — |
| 28 Aug 2026 · QIP completed - 2.11 cr shares allotted at Rs 354 each, raising Rs 750 cr | fund raising | high | — | — |
| 28 Aug 2026 · QIP closes at Rs 354/share; company raises about Rs 75 crore | fund raising | high | — | — |
| 27 Aug 2026 · Board meeting on Sept 1 to consider fund raise via preferential issue | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 415.7 | 28.9 | 167 of 169 | 1% |
| EBITDA margin | 47.8 | 17.5 | 4 of 165 | 98% |
| Market cap | 4620 | 839 | 59 of 182 | 68% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
